<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220088</url>
  </required_header>
  <id_info>
    <org_study_id>HCC201408</org_study_id>
    <nct_id>NCT02220088</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial</brief_title>
  <official_title>The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transarterial chemoembolization (TACE) is considered the gold standard for treating
      intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not
      specify the criteria for repeating TACE.The study,conducted in Europe ，recently published in
      the journal of Hepatology shows the ART score of &gt;=2.5 prior the second TACE identifies
      patients with a dismal prognosis who may not profit from further TACE sessions. However,in
      clinical practice，we also found some patients who showed TACE-resistant at the beginning of
      treatment may access to get objective response of retreatment with TACE.So the investigators
      conduct this prospective,randomized controlled study to find out whether the patient who
      showed TACE-resistant can obtain survival benefit from retreatment with TACE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transarterial chemoembolization (TACE) is considered the gold standard for treating
      intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a
      heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh
      A or B) and disease aetiology.This suggests that not all patients with intermediate-stage HCC
      will derive similar benefit from TACE, and that some patients may benefit from other
      treatment options.

      Repetition of TACE is based on evidence suggesting that one cycle of TACE may not be
      sufficient for effective treatment of intermediate-stage HCC and repeating TACE prolongs
      survival.However, intermediate-stage HCC patients often have unsatisfactory clinical outcomes
      with repeated TACE and there is not sufficiently addressed by existing guidelines include the
      criteria for repeating TACE and recommendations about the number of TACE cycles to be
      repeated before switching to another or no treatment.The study,recently published in the
      journal of Hepatology shows the ART score of &gt;=2.5 prior the second TACE identifies patients
      with a dismal prognosis who may not profit from further TACE sessions.In clinical
      practice，however, we also found some patients who showed TACE-resistant at the beginning of
      treatment may access to get objective response of retreatment with TACE.So we conduct this
      prospective,randomized controlled study to find out whether the patient who showed
      TACE-resistant can obtain survival benefit from retreatment with TACE.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>All severe adverse events for the entire course of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retreatment With Transarterial Chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NON-TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with other than TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Retreatment with TACE: an embolization suspension consisting of mitomycin C, lobaplatin , epirubicin, iodized-oil (Lipiodol; Guerbet, Aulnay-sous-Bois, France), and gelatin-sponge particles.</description>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-TACE</intervention_name>
    <description>Accept treatments other than TACE,such as sorafenib,radiotherapy,Best support conservative treatment and so on.</description>
    <arm_group_label>NON-TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients， &gt; 18 years and &lt;=70 years old diagnosed with HCC according to
             the European Association for the Study of the Liver (EASL) diagnostic criteria

          -  The patient has received 1 session of TACE

          -  BCLC stage B disease

          -  Cirrhotic status of Child-Pugh class A or B

          -  Patients with an ART score &gt;=2.5 points after 1 TACE session

          -  The following laboratory parameters:

               -  Platelet count ≥ 60,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or PT/APTT within normal limits

               -  Absolute neutrophil count (ANC) &gt;1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Patients with complete response (CR) after the first TACE did not receive a further
             TACE session

          -  Eastern Cooperative Oncology Group (ECOG) &gt;1

          -  Interval TACEn-TACEn-1&gt;90 days

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Evidence of bleeding diathesis.

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Severe Arterioportal Shunts or Arteriavein Shunts

          -  Known central nervous system tumors including metastatic brain disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center, Sun Yat-set University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi</last_name>
    <phone>86-2087343154</phone>
    <phone_ext>86-2087343154</phone_ext>
    <email>shiming@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Ping Guo</last_name>
    <phone>86-2087342266</phone>
    <phone_ext>86-2087342266</phone_ext>
    <email>guorongp@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi</last_name>
      <phone>86-2087343154</phone>
      <phone_ext>86-2087343154</phone_ext>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ping Rong , Guo</last_name>
      <phone>86-2087342266</phone>
      <phone_ext>86-2087342266</phone_ext>
      <email>guorongp@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011 May;37(3):212-20. doi: 10.1016/j.ctrv.2010.07.006. Epub 2010 Aug 17. Review.</citation>
    <PMID>20724077</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8. Review.</citation>
    <PMID>23397536</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013 Mar;33(3):327-37. doi: 10.1111/liv.12083. Epub 2013 Jan 18. Review.</citation>
    <PMID>23331661</PMID>
  </results_reference>
  <results_reference>
    <citation>Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013 Jun;57(6):2261-73. doi: 10.1002/hep.26256. Epub 2013 May 3.</citation>
    <PMID>23316013</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int. 2014 Feb;34(2):174-83. doi: 10.1111/liv.12314. Epub 2013 Nov 20. Review.</citation>
    <PMID>24251922</PMID>
  </results_reference>
  <results_reference>
    <citation>Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014 Jan;60(1):118-26. doi: 10.1016/j.jhep.2013.08.022. Epub 2013 Sep 3.</citation>
    <PMID>24012941</PMID>
  </results_reference>
  <results_reference>
    <citation>Yousuf F, Cross TJ, Palmer D. The ART strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014 Jul;61(1):175. doi: 10.1016/j.jhep.2014.02.032. Epub 2014 Mar 18.</citation>
    <PMID>24657396</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>TACE</keyword>
  <keyword>TACE failure</keyword>
  <keyword>TACE refractoriness</keyword>
  <keyword>BCLC B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

